<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01854463</url>
  </required_header>
  <id_info>
    <org_study_id>CSHH2011-64</org_study_id>
    <secondary_id>KDA2010</secondary_id>
    <nct_id>NCT01854463</nct_id>
  </id_info>
  <brief_title>The Effect of Vitamin D Supplementation in Type 2 Diabetes</brief_title>
  <acronym>VD2000</acronym>
  <official_title>The Effect of Vitamin D Supplementation on the Glycemic Control and Non-alcoholic Fatty Liver Disease in Type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chuncheon Sacred Heart Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Korean Diabetes Association</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Chuncheon Sacred Heart Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In many observational studies, vitamin D deficiency is related to glucose intolerance and
      diabetes. But there little randomized, controlled interventional studies that evaluate the
      effect of vitamin D in type 2 diabetes.

      Investigators investigate the effect of high dose (2000IU) 25-hydroxy vitamin D on type 2
      diabetes in glycemic controls, non-alcholic fatty liver disease, and arterial stiffness, and
      bone turnover markers.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      After informed consent, investigators randomized 180 type 2 diabetes into interventiona group
      (25-hydroxy vitamin d 2000 IU+ elemental calcium 200mg per day) or placebo group (elemental
      calcium 200mg per day). The participants should control diabetes by oral medications or
      lifestyle intervention at the intervention period. Investigators exclude the participants who
      took vitamin D or calcium or anti-osteoporotic drugs. Investigators also exclude renal
      insufficiency (Cr&gt;1.5 in men or Cr&gt;1.4 in women) or heavy alcoholics.

      Investigators followed the participants for 24 weeks. After randomization, investigators
      checked HbA1c,glucose, calcium, 25-hydroxyvitamin d, AST, ALT,Creatinine, Parathyroid
      hormone, bone-specific alkaline phosphatase, serum CTX, brachial-ankle pulse wave velocity,
      central blood pressure, and aortic augmentation index, and precontrast liver computed
      tomography. Also investigators checked body weight, height, and peripheral blood pressure.

      At 12 weeks, investigators checked HbA1c, 25-hydroxy vitamin D, AST, ALT, calcium, and
      creatinine.

      At the end of the study(at 24 weeks), investigators checked HbA1c, glucose, AST, ALT,
      Creatinine, calcium, bone-specific alkaline phosphatase, serum CTX, brachial-ankle pulse wave
      velocity, central blood pressure, aortic augmentation index, and precontrast liver computed
      tomography.

      After the study completed, investiators compared the data of interventional groups and
      placebo groups.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2011</start_date>
  <completion_date type="Actual">February 2013</completion_date>
  <primary_completion_date type="Actual">October 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>glycemic control</measure>
    <time_frame>0, 12week, and 24week</time_frame>
    <description>Investigators checked glycemic control status at the enrollment, 12-week, 24- week by HbA1c</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>arterial stiffenss</measure>
    <time_frame>at 0 and 24-week</time_frame>
    <description>central blood pressure brachial-ankle pulse wave velocity aortic augmentation index</description>
  </secondary_outcome>
  <other_outcome>
    <measure>non-alcoholic fatty liver diseases and bone turnover marker</measure>
    <time_frame>at 0 and 24- week</time_frame>
    <description>precontrast liver computed tomography AST, ALT calcium, PTH, bone specific alkaline phosphatase, serum CTX, calcium</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">158</enrollment>
  <condition>DIABETES MELLITUS</condition>
  <arm_group>
    <arm_group_label>Vitamin D3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>25-hydroxy vitamin d 2000 IU and elemeental calcium 200mg daily for 24 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>administered elemental calcium 200mg daily for 24 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vitamin D3</intervention_name>
    <description>2000IU per day</description>
    <arm_group_label>Vitamin D3</arm_group_label>
    <other_name>dicamax d</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>elemental calcium 200mg per day per 24 weeks</description>
    <arm_group_label>placebo</arm_group_label>
    <other_name>calcium</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  TYPE 2 DIABETES MELLITUS PATIENTS WHO CONTROL GLUCOSE BY ORAL ANTIBIABETIC DRUGS OR
             LIFESTYLE ONLY

          -  DID NOT CHANGE ANTIDIABETIC DRUG BEFORE THE STUDY FOR 2 MONTHS

          -  normal physical activity

          -  30 to 69 years

          -  &gt;=6.5% OR &lt;8.0% OF HbA1c

        Exclusion Criteria:

          -  Creatinine&gt;1.5 in men, &gt;1.4 in women

          -  heavy alcoholics

          -  who took calcium or vitamin d or anti-osteoporosis drug within 3 months before the
             study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>69 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>OHKHYUN RYU, PROFESSOR</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hallym University Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Chuncheon Sacred Heart Hospital</name>
      <address>
        <city>Chuncheon</city>
        <state>Gangwon-do</state>
        <zip>200704</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <reference>
    <citation>Breslavsky A, Frand J, Matas Z, Boaz M, Barnea Z, Shargorodsky M. Effect of high doses of vitamin D on arterial properties, adiponectin, leptin and glucose homeostasis in type 2 diabetic patients. Clin Nutr. 2013 Dec;32(6):970-5. doi: 10.1016/j.clnu.2013.01.020. Epub 2013 Feb 27.</citation>
    <PMID>23561637</PMID>
  </reference>
  <verification_date>May 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 19, 2013</study_first_submitted>
  <study_first_submitted_qc>May 9, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 15, 2013</study_first_posted>
  <last_update_submitted>May 9, 2013</last_update_submitted>
  <last_update_submitted_qc>May 9, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 15, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chuncheon Sacred Heart Hospital</investigator_affiliation>
    <investigator_full_name>OHKHYUN RYU</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>DIABETES MELLITUS</keyword>
  <keyword>VITAMIN D</keyword>
  <keyword>ARTERIAL STIFFNESS</keyword>
  <keyword>FATTY LIVER</keyword>
  <keyword>BONE TURNOVER</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
    <mesh_term>Cholecalciferol</mesh_term>
    <mesh_term>Calcium, Dietary</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

